Novel concepts in HDL pharmacology

Cardiovascular Research

Volumn 103, Issue 3, 2014, Pages 423-428

  Remaley, Alan T ^a   Norata, Giuseppe D ^b,c,d   Catapano, Alberico L ^b,e  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c Center for the Study of Atherosclerosis Ospedale Bassiniz   (Italy)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e IRCCS MULTIMEDICA   (Italy)

Author keywords

Atherosclerosis; Cardiovascular disease; Cholesterol; Drugs; HDL

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; NICOTINIC ACID; SCAVENGER RECEPTOR BI INHIBITOR; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ALTERNATIVE MEDICINE; CHOLESTEROL TRANSPORT; HUMAN; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG DESIGN; DYSLIPIDEMIAS; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DRUG DESIGN; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME; UP-REGULATION;

EID: 84905590168     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu141     Document Type: Review

References (75)

1. Barter P. HDL-C: Role as a risk modifier. Atheroscler Suppl 2011;12:267-270
2. Rader DJ. Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med 2007;4:102-109
3. Escola-Gil JC, Calpe-Berdiel L, Palomer X, Ribas V, Ordonez-Llanos J, Blanco-Vaca F. Antiatherogenic role of high-density lipoproteins: Insights from genetically engineeredmice. Front Biosci 2006;11:1328-1348
4. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 2012;125:1905-1919
5. Rosenson RS, Brewer HB, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011; 57:392-410
6. Pirillo A, Norata GD, Catapano AL. Treating high density lipoprotein cholesterol (HDL-C): Quantity versus quality. Curr Pharma Design 2013;19:3841-3857
7. Pirillo A, Norata GD, Catapano AL. High-density lipoprotein subfractions-what the clinicians need to know. Cardiology 2013;124:116-125
8. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Nyaku M, Horvath KV, Asztalos BF, Otokozawa S, Ai M, Matthan NR, Lichtenstein AH, Dolnikowski GG, Schaefer EJ. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008;28: 1672-1678
9. Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: Will they be useful therapeutic agents?. Am J Cardiol 2007;100:S53-S61
10. Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs. Eur Heart J 2013;34:1783-1789
11. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K,WeintraubW. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267
12. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-1291
13. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, JayeM, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR-Alpha and PPARgamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001;7:53-58
14. Franceschini G, Calabresi L, Colombo C, Favari E, Bernini F, Sirtori CR. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 2007;195:385-391
15. Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 2006;42:39-64
16. Shah A, Rader DJ, Millar JS. The effect of PPAR-Alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010;210:35-40
17. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005;96:1221-1232
18. Parini P, Rudel LL. Is there a need for cholesteryl ester transfer protein inhibition?. Arterioscler Thromb Vasc Biol 2003;23:374-375
19. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122
20. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M 3rd,West SH, White V,Woltmann RF. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008;154:1465-1473
21. Rader DJ. Illuminating HDL-is it still a viable therapeutic target?. N Engl J Med 2007;357: 2180-2183
22. Luscher TF, Taddei S, Kaski JC, JukemaJW, Kallend D, Munzel T, Kastelein JJ, Deanfield JE. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: The dal-VESSEL randomized clinical trial. Eur Heart J 2012;33:857-865
23. Fayad ZA, Mani V,Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A. Safetyand efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): A randomised clinical trial. Lancet 2011;378:1547-1559
24. Ford J, Lawson M, Fowler D, Maruyama N, Mito S, Tomiyasu K, Kinoshita S, Suzuki C, Kawaguchi A, Round P, Boyce M, Warrington S, Weber W, van Deventer S, Kastelein JJ. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 2014; doi:10.1111/bcp.12380
25. Vakalopoulos A, Schmeck C, Thutewohl M, Li V, Bischoff H, Lustig K, Weber O, Paulsen H, Elias H. Chromanol derivatives-A novel class of CETP inhibitors. Bioorganic Med Chem Lett 2011;21:488-491
26. Picaud S,Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, Diez-Dacal B, Philpott M, Bountra C, Lingard H, Fedorov O, Muller S, Brennan PE, Knapp S, Filippakopoulos P. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci USA 2013;110:19754-19759
27. Nicholls SJ, Gordon A, Johansson J, Wolski K, Ballantyne CM, Kastelein JJ, Taylor A, Borgman M, Nissen SE. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol 2011;57:1111-1119
28. Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, Hovingh GK, HoekstraM, Sierts JA, Dallinga-Thie GM, Motazacker MM, Holleboom AG, Van Berkel TJ, Kastelein JJ, Van Eck M, Kuivenhoven JA. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011;364:136-145
29. Brunham LR, Tietjen I, Bochem AE, Singaraja RR, Franchini PL, Radomski C, Mattice M, Legendre A, Hovingh GK, Kastelein JJ, Hayden MR. Novelmutations in scavenger receptor BI associated with high HDL cholesterol in humans. Clin Genet 2011;79:575-581
30. Mineo C, Shaul PW. Functions of scavenger receptor class B, type I in atherosclerosis. Curr Opin Lipidol 2012;23:487-493
31. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL. An interplay between hypervariable region 1 of the hepatitisCvirus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005;79: 8217-8229
32. Voisset C, Callens N, Blanchard E, OpDe Beeck A, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitisCvirus entry through the scavenger receptor class B type I. J Biol Chem 2005;280:7793-7799
33. von Hahn T, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, Rice CM, McKeating JA. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 2006;43:932-942
34. Norata GD, Pirillo A, Ammirati E, Catapano AL. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 2012;220:11-21
35. Norata GD, Pirillo A, Catapano AL. HDLs, immunity, and atherosclerosis. Curr Opin Lipidol 2011;22:410-416
36. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A. Role of scavenger receptor class B type I in hepatitis C virus entry: Kinetics and molecular determinants. J Virol 2010;84:34-43
37. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A. High-Avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007;81:8063-8071
38. MassonD, Koseki M, IshibashiM, Larson CJ, Miller SG, King BD, Tall AR. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol 2009;29:2054-2060
39. NorataGD, Sala F, Catapano AL, Fernandez-Hernando C. MicroRNAs and lipoproteins: A connection beyond atherosclerosis?. Atherosclerosis 2013;227:209-215
40. Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-Activated receptors LXR and FXR. Nat Rev Mol Cell Biol 2012;13:213-224
41. Katz A, Udata C, Ott E, Hickey L, Burczynski ME, Burghart P, Vesterqvist O, Meng X. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol 2009;49:643-649.
42. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116: 281-297
43. Condorelli G, Latronico MV, Dorn GW II. microRNAs in heart disease: Putative novel therapeutic targets?. Eur Heart J 2010;31:649-658
44. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, Leclercq IA, Macdougald OA, Bommer GT. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2011;121:2921-2931
45. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA 2010;107:12228-12232
46. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566-1569
47. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernandez-Hernando C. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010;328:1570-1573
48. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, Fernandez-Hernando C, Fisher EA, Moore KJ. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest
49. Calabresi L, Simonelli S, Gomaraschi M, Franceschini G. Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis 2012;222: 299-306
50. Baragetti A, Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, Uboldi P, Baragetti I, Pozzi C, Catapano AL. High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Int Med 2013;274: 252-262
51. Simonelli S, Tinti C, Salvini L, Tinti L, Ossoli A, Vitali C, Sousa V, Orsini G, Nolli ML, Franceschini G, Calabresi L. Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency. Biologicals: J Int Assoc Biol Standard 2013;41:446-449
52. Rousset X, Vaisman B, Stonik J, Duarte C, Remaley A. Effect of rapid infusion of LCAT on HDL metabolism and its possible utility for enzyme replacement therapy. Atherosclerosis 2009;abstract e445
53. Rousset X, Vaisman B, Auerbach B, Krause BR, Homan R, Stonik J, Csako G, Shamburek R, Remaley AT. Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice. J Pharmacol Exp Therap 2010;335: 140-148
54. Shamburek R, Freeman L, Sampson M, Bakker-Arkema R, Krause BR, Auerbach B, Homan R, Shamburek A, Schwartz C, Amar M, Remaley AT. Human enzyme replacement therapy in a patient with familial lecithin cholesterol acyltransferase deficiency: Rapid appearance of normal appearing HDL. Circulation 2013;128:A18673
55. Remaley AT, Amar M, Sviridov D. HDL-replacement therapy: Mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther 2008;6: 1203-1215
56. Krause BR, Remaley AT. Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol 2013;24:480-486
57. Trogan E, Feig JE, Dogan S, Rothblat GH, AngeliV, Tacke F, Randolph GJ, Fisher EA. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 2006;103: 3781-3786
58. Dobesh PP, Beavers CJ, Herring HR, Spinler SA, Stacy ZA, Trujillo TC. Key articles and guidelines in the management of acute coronary syndrome and in percutaneous coronary intervention: 2012 update. Pharmacotherapy 2012;32:e348-e386
59. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003;290:2292-2300
60. Nicholls SJ, Uno K, Tuzcu EM, Nissen SE. Lessons from coronary intravascular ultrasound on the importance of raising high-density lipoprotein cholesterol. Curr Atherosclerosis Rep 2010;12:301-307
61. Tardif JC GJ, LAllier PL, Ibrahim R, Lesperance J, Heinonen TM,Kouz S, Berry C, Basser R, Lavoie MA GM, Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 2007;297: 1675-1682
62. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N,Woollard K, Lyon S, Sviridov D, Dart AM. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008;103:1084-1091
63. Calabresi L, Canavesi M, Bernini F, Franceschini G. Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. Biochemistry 1999;38:16307-16314
64. Diditchenko S, Gille A, Pragst I, Stadler D,Waelchli M, Hamilton R, Leis A, Wright SD. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol 2013;33: 2202-2211
65. Segrest JP, De Loof H, Dohlman JG, Brouillette CG, Anantharamaiah GM. Amphipathic helix motif: Classes and properties. Proteins 1990;8:103-117
66. Remaley AT, Thomas F, Stonik JA, Demosky SJ, Bark SE, Neufeld EB, Bocharov AV, Vishnyakova TG, Patterson AP, Eggerman TL, Santamarina-Fojo S, Brewer HB. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 2003;44:828-836
67. Osei-Hwedieh DO,Amar M, Sviridov D, RemaleyAT. Apolipoprotein mimetic peptides: Mechanisms of action as anti-Atherogenic agents. Pharmacol Therap 2011;130:83-91
68. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, Eggerman TL, Patterson AP, Duverger NJ, Santamarina-Fojo S, Brewer HB Jr. Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun 2001;280:818-823
69. Amar MJA, DSouzaW, Turner S, Demosky S, Sviridov D, Stonik J, Luchoomun J, Voogt J, Hellerstein M, Sviridov D, Remaley AT. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Therap 2010; 334:634-641
70. Bloedon LT, DunbarR, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, MovvaR, Navab M, Fogelman AM, Rader DJ. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008;49: 1344-1352
71. Van Lenten BJ, Navab M, Anantharamaiah GM, Buga GM, Reddy ST, Fogelman AM. Multiple indications for anti-inflammatory apolipoprotein mimetic peptides. Curr Opin Investig Drugs 2008;9:1157-1162
72. Navab M,Hough G, BugaGM,Su F,WagnerAC,Meriwether D, ChattopadhyayA,GaoF, Grijalva V, Danciger JS, Van Lenten BJ, Org E, Lusis AJ, Pan C, Anantharamaiah GM, Farias-Eisner R, Smyth SS, Reddy ST, Fogelman AM. Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J Lipid Res 2013;54: 3403-3418
73. Remaley AT. Tomatoes, lysophosphatidic acid, and the small intestine: New pieces in the puzzle of apolipoprotein mimetic peptides?. J Lipid Res 2013;54:3223-3226
74. Bielicki JK, ZhangH, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, Azhar S. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 2010;51:1496-1503
75. Sethi AA, Stonik JA, Thomas F, Demosky SJ, Amar M, Neufeld E, Brewer HB, Davidson WS, DSouza W, Sviridov D, Remaley AT. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1- dependent cholesterol efflux by peptides. J Biol Chem 2008;283:32273-32282